Molecular Matrix, Inc. (MMI) was incorporated in August 2011 as a preclinical stage biotechnology company. MMI is dedicated to developing an innovative new generation platform tissue regeneration technology for musculoskeletal applications, specifically bone.
Our first product is a non-mineralized bone graft substitute intended for use in a multitude of different applications and treatments, such as filling defects in orthopedic surgery. MMI’s polymer technology eliminates the inherent disadvantages associated with current bone graft substitute, including disease transmission, insufficient bone formation, inadequate absorption, and interference with evaluation of bone formation by imaging modalities. We can provide the product as granules, sheets, blocks, and cylinders for general orthopedic applications.